Is there a role for pleiotropic effects of atorvastatin and fenofibrate in the metabolic syndrome and prediabetes?
Authors:
- 1 November 2010
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 5 (6) , 835-837
Abstract
The beneficial use of fibrates and statins has been observed in previous studies among patients with dyslipidemia, including those with glucose metabolism abnormalities. The paper under evaluation highlights these benefits and provides insight. Specifically, these findings are observed in patients who have prediabetes and metabolic syndrome (MS), and are taking atorvastatin or fenofibrate. The paper documents that both drugs have multiple pleiotropic effects on MS patients. Furthermore, these effects may be determined by prediabetes type. The results strengthen previous knowledge and offer new understanding, as no previous study has investigated whether the type of prediabetes can determine extra- lipid effects and cardiovascular risk factors in MS patients.Keywords
This publication has 11 references indexed in Scilit:
- Pleiotropic Effects of Atorvastatin and Fenofibrate in Metabolic Syndrome and Different Types of Pre-DiabetesDiabetes Care, 2010
- Regulatory Effects of Fenofibrate and Atorvastatin on Lipoprotein A-I and Lipoprotein A-I:A-II Kinetics in the Metabolic SyndromeDiabetes Care, 2009
- Atorvastatin and Fenofibrate Have Comparable Effects on VLDL-Apolipoprotein C-III Kinetics in Men With the Metabolic SyndromeArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Fibrates and future PPARα agonists in the treatment of cardiovascular diseaseNature Clinical Practice Cardiovascular Medicine, 2008
- Targeting vascular risk in patients with metabolic syndrome but without diabetesMetabolism, 2005
- Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemiaJournal of Lipid Research, 2004
- Epidemic Obesity and the Metabolic SyndromeCirculation, 2003
- Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic SyndromeDiabetes, 2003
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminNew England Journal of Medicine, 2002
- Mechanism of Action of Fibrates on Lipid and Lipoprotein MetabolismCirculation, 1998